Biocompatibility of biomaterials: Hemocompatibility, immunocompatibility and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers

Advanced Drug Delivery Reviews

Volumn 21, Issue 2, 1996, Pages 157-176

  Říhová, Blanka ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

defense response; drug carriers; drug targeting; hemocompatibility; immunocompatibility; immunogenicity; inflammatory response; pharmacokinetics; polymer implants; polymeric materials

Indexed keywords

ANTIGENS; BIOCOMPATIBILITY; CARDIOVASCULAR SURGERY; CELLS; CONTROLLED DRUG DELIVERY; DIALYSIS MEMBRANES; ENCAPSULATION; HORMONES; IMMUNOLOGY; IMPLANTS (SURGICAL); PLASTIC COATINGS; POLYMERS;

CARDIOPULMONARY BYPASS; DEFENSE RESPONSE; DRUG CARRIERS; DRUG TARGETING; GROWTH FACTORS; HEMOCOMPATIBILITY; IMMUNOCOMPATIBILITY; IMMUNOGENICITY; INFLAMMATORY RESPONSE; POLYMERIC CARRIERS;

BIOMATERIALS;

2 HYDROXYETHYL METHACRYLATE; ALGINIC ACID; BIOMATERIAL; CARBOMER; CHITOSAN; COMPLEMENT; CYTOKINE; DRUG CARRIER; ENZYME; GROWTH FACTOR; HORMONE; HYDROXYPROPYLMETHYLCELLULOSE; METHACRYLIC ACID METHYL ESTER; MICROSPHERE; POLY(3 HYDROXYBUTYRIC ACID); POLY(METHYL METHACRYLATE); POLYACRYLIC ACID; POLYGLYCOLIC ACID; POLYMER; POLYURETHAN; POVIDONE; SCLEROGLUCAN; UNINDEXED DRUG; XANTHAN;

BIOCOMPATIBILITY; BLOOD CLOTTING; BLOOD COMPATIBILITY; CARDIOPULMONARY BYPASS; DIALYSIS; DRUG RELEASE; DRUG TARGETING; ENCAPSULATION; HOST RESISTANCE; HUMAN; IMMUNITY; IMPLANT; INFLAMMATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SOLID; SOLUBILITY;

EID: 0030590503     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00404-8     Document Type: Review

References (188)

1. [1] Vienken, J., Diamantoglou, M., Hahn, C., Kamusewitz, H. and Paul, D. (1995) Considerations on developmental aspects of biocompatible dialysis membranes. Artif. Organs 19, 398-406.
2. [2] Remes, A. and Williams, D.F. (1992) Immune response in biocompatibility. Biomaterials 13. 731-743.
3. [3] Gould, J., Liebler, B., Baier, R., Benson, J., Boretos, J., Callahan, T., Canty, E., Compton, R., Marlowe, D., O'Holla, R., Page, B., Paulson, J. and Swanson, C. (1993) Biomaterials availability: development of a characterization strategy for interchanging silicone polymers in implantable medical devices. J. Appl. Biomater. 4, 355-358.
4. [4] Říhová, B., and Říha, I. (1985) Immunological problems of polymer-bound drugs. CRC Crit. Rev. Ther. Drug. Carr. Syst. 1, 311-374.
5. [5] Klinkmann, H., Falkenhagen, D., Stefoni, S. and Bonomini, V. (1989) Biocompatibility, a system approach. Contrib. Nephrol. 70, 213-226.
6. [6] Maillet, F., Labarre, D. and Kazatchkine, M.D. (1990) The role of naturally-occuring antibodies against manmade materials in biocompatibility. Transfus. Sci. 11, 33-41.
7. [7] Nalbandian, R.M., Swanson, A.B. and Maupin, B.K. (1983) Long-term results of silicone implant arthroplasty. Implications of animal and human autopsy findings. J. Am. Med. Assoc. 250, 1195-1198.
8. [8] Gordon, M. and Bullough, P.G. (1982) Synovial and osseous inflammation in failed silicone-rubber prostheses. J.Bone Joint Surg. (Am.) 64, 574-580.
9. [9] Goldblum, R.N., Pelley, R.P., O'Donell, A.A., Pyron, D. and Heggers, J.P. (1992) Antibodies to silicone elastomers and reactions to ventriculoperitoneal shunts. Lancet 340, 510-513.
10. [10] Elves, M.M., Wilson, J.M., Scales, J.T., Kemp, H.B.S. (1975) Incidence of metal sensitivity in patients with total joint replacements. Br. Med. J. 4, 376-378.
11. [11] Klompmaker, J., Jansen, H.W.B., Veth, R.P.H., deGroost, J.H., Nijenhuis, A.J. and Pennings, A.J. (1991) Porous polymer implant for repair of meniscal lesions: a preliminary study in dogs. Biomaterials 12, 810-816.
12. [12] Kircher, T. (1980) Silicone lymphadenopathy. A complication of silicone elastomer finger joint prostheses. Hum. Pathol. 11, 240-244.
13. [13] Peimer, C.A., Medige, J., Eckert, B.S., Wright, J.R. and Howard, C.S. (1986) Reactive synovitis after silicone arthroplasty. J. Hand Surg. 11A, 624-638.
14. [14] Heggers, J.P., Kossovsky, N., Parsons, R.W., Robson, M.C., Pelley, R.P. and Raine, T.J. (1983) Biocompatibility of silicone implants. Ann. Plast. Surg. 11, 38-45.
15. [15] Roccatello, D., Formica, M., Cavalli, G., Quattrocchio, G., Aimo, G., Polloni, R., Amprimo, M.C., Molino, A., Martina, G., Isidoro, C., Mazengo, M., Coppo, R., Sena, L.M. and Piccoli, G. (1992) Serum and intracellular detection of cytokines in patients undergoing chronic hemodialysis. Artif. Organs 16, 131-140.
16. [16] Jerstad, S., Smeby, L.C., Balstad, T. and Wideroe, T.E. (1988) Generation and removal of anaphylatoxins during hemofiltration with 5 different membranes. Blood Purif. 6, 325-335.
17. [17] Hörl, W.H., Riegel, W. and Schollmeyer, P. (1986) Different complement and granulocyte activation in patients dialyzed with PMMA dialyzers. Clin. Nephrol. 25, 304-307.
18. [18] Ward, R., Klein, E., Harding, G. and Murchison, K. (1989) Response of complement and neutrophils to hydrophilized synthetic membranes. Tran. ASAIO 34, 334-337.
19. [19] Chenoweth, D.E. and Henderson, L.W. (1987) Complement activation during hemodialysis: laboratory evaluation of hemodialyalizers. Artif. Organs 11, 155-162.
20. [20] Henderson, L.W. and Chenoweth, D. (1987) Biocompatibility of artificial organs: an overview. Blood membrane interaction in extracorporeal circuits. Blood Purif. 5, 100-111.
21. [21] Hakim, R.M., Fearon, D.T. and Lazarus, J.M. (1984) Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int. 26, 94-99.
22. [22] Magilligan, D.J., Lewis, J.W. Jr, Heinzerlng, R.H. and Smith. D. (1983) Fate of a second porcine bioprosthetic valve. J. Thorac. Cardiovasc. Surg. 85, 362-370.
23. [23] Tanaka, K., Sato, T., Kondo, CH., Yada, I., Yuasa, H., Kusagawa, M., Nasu, M., Okada, Y. and Shomura, T. (1992) Hematological problems during the use of cardiac assist devices: clinical experiences in Japan. Artif. Organs 16, 182-188.
24. [24] De Scheerder, I.K., Wilczek, K.L., Verbeken, E.V., Vandorpe, J., Lan, P.N., Schacht, E., De Geest, H. and Piessens, J. (1995) Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 114, 105-114.
25. [25] Cenni, E., Cavedagna, D., Falsone, G., Mari, G. and Pizzoferrato, A. (1993) Numerical and functional modification in platelets induced by polyester coated by a hydrophilic polymer. Biomaterials 14, 588-590.
26. [26] Marchant, R.E., Johnson, S.D., Schneider. B.H., Agger, M.P. and Anderson, J.M. (1990) A hydrophilic plasma polymerized film composite with potential application as an interface for biomaterials. J. Biomed. Mater. Res. 24, 1521-1527.
27. [27] Matsuda, T. and Ito, S. (1994) Surface coating of hydrophilic-hydrophobic block co-polymers on a poly(acrylonitrile) haemodialyser reduces platelet adhesion and its transmembrane stimulation. Biomaterials 15, 417-422.
28. [28] Ruckenstein, E. and Gourisankar, S.V. (1986) Preparation and characterization of thin film surface coatings for biological environments. Biomaterials 7, 403-422.
29. [29] Quinn, C.P., Pathak, C.P., Heller, A. and Hubbell, J.A. (1995) Photo-crosslinked copolymers of 2-hydroxyethyl methacrylate, poly(ethylene glycol)tetra-acrylate and ethylene dimethacrylate for improving biocompatibility of biosensors. Biomaterials 16, 389-396.
30. [30] Cohen, S., Alonso, M.J. and Langer, R. (1994) Novel approaches to controlled-release antigen delivery. Int. J. Technol. Assess. Health Care 10, 121-130.
31. [31] Men, Y., Thomasin, C., Merkle, H.P., Gander, B. and Corradin, G. (1995) A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminium hydroxide. Vaccine 13, 683-689.
32. [32] Kawaguchi, T., Tsugane, A., Higashide, K., Endoh, H., Hasegawa, T., Kanno, H., Seki, T., Juni, K., Fukushima, S. and Nakano, M. (1992) Control of drug release with a combination of prodrug and polymer matrix: antitumor activity and release profiles of 2,3-diacyl-5-fluoro-2 deoxyuridine from poly(3-hydroxybutyrate) microspheres. J. Pharm. Sci. 81, 508-512.
33. [33] O'Haggan, D.T., Rahman, D., McGee, J.P., Jeffrey, H., Davies, M.C., Williams, P., Davis, S.S. and Challacombe, S.J. (1991) Biodegradable microparticles as controlled release systems. Immunology 73, 239-242.
34. [34] Trevor, P.B., Stevenson, S., Carrig, C.B., Waldron, D.R. and Smith, M.M. (1992) Evaluation of biocompatible osteoconductive polymer as an orthopedic implant in dogs. J. Am. Vet. Med. Assoc. 200, 1651-1660.
35. [35] Lescure, F., Gurny, R., Doelker, E., Pelaprat, M.L., Bichon, D. and Anderson, J.M. (1989) Acute histopathological response to a new biodegradable polypeptidic polymer for implantable drug delivery system. J. Biomed. Mater. Res. 23, 1299-1313.
36. [36] Brem, H., Kader, A., Epstein, J.I., Tamargo, R.J., Domb, A., Langer, R. and Leong, K.W. (1989) Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Sel. Cancer Ther. 5, 55-65.
37. [37] Radder, A.H., Davies, J.E., Leenders, H. and van Blitterswijk, C.A. (1994) Interfacial behavior of PEO/ PBT copolymers (Polyactive) in a calvarial system: an in vitro study. J. Biomed. Mater. Res. 28, 269-277.
38. [38] Korbelář, P., Vacik, J., Dylevsky, I. (1988) Experimental implantation of hydrogel into the bone. J. Biomed. Mater. Res. 22, 751-762.
39. [39] Jeyanthi, R. and Rao, K.P. (1990) In vivo biocompatibility of collagen-poly(hydroxyethyl methacrylate) hydrogels. Biomaterials 11, 238-243.
40. [40] Esposito, P., Colombo, I. and Lovrecich, M. (1994) Investigation of surface properties of some polymers by a thermodynamic and mechanical approach: possibility of prediciting mucoadhesion and biocompatibility. Biomaterials 15, 177-182.
41. [41] Khansari, D.N., Murgo, A.J. and Faith, R.E. (1990) Effects of stress on the immune system. Immunol. Today 11, 170-175.
42. [42] Kushner, I. (1982) The phenomenon of the acute phase response. Ann. NY Acad. Sci. 89, 39-48.
43. [43] Koj, A. (1985) Biological functions of acute-phase proteins. In: A.H. Gordon and A. Koj (Eds.), The Acute-Phase Response to Injury and Infection: The Roles of Interleukin 1 and Other Mediators, Vol. 10. Elsevier, Amsterdam, pp. 145-160.
44. [44] Fey, G. and Gauldie, A. (1990) The acute phase reponse of the liver in inflammation. Prog. Liver Dis. 9, 89-116
45. [45] Baumann, H. and Gauldie, J. (1990) Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol. Biol. Med. 7, 147-159.
46. [46] Crockson, R.A., Payne, C.J., Ratcliff, A.P. and Soothill, J.F. (1966) Time sequence of acute phase reactive proteins following surgical trauma. Clin. Chim. Acta 14, 435-441.
47. [47] Fisher, C.L., Gill, C., Forrester, M.G. and Nakamura, R (1976) Quantitation of 'acute-phase proteins' postoperatively. Value in detection and monitoring of complication. Am. J. Clin. Pathol. 66, 840-846.
48. [48] Fleck, A. and Myers, M.A. (1985) Diagnostic and prognostic significance of the acute-phase proteins. In: J. Gordon and A. Koj (Eds.), The Acute-Phase Response to Injury and Infection, Vol. 10. Elsevier, Amsterdam, pp. 249-271.
49. [49] Price, C.P., Trull, A.K., Berry, D. and Gorman, E.G. (1987) Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein. J. Immunol. Methods 99, 205-211.
50. [50] Dunn, J.C.Y., Tompkins, R.G. and Yarmush, M.L. (1991) Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol. Prog. 7, 237-245.
51. [51] Hogevold, H.E., Kierulf, P., Ovstebo, R. and Reikaras, O. (1992) Acute phase reactants and interleukin 6 after total hip replacement. Eur. J. Surg. 158, 339-345.
52. [52] Jones, D.A., Smith, C.W. and McIntire, L.V. (1996) Leucocyte adhesion under flow conditions: principles important in tissue engineering. Biomaterials 17: 337-347.
53. [53] Balkwill, F.R. and Burke, F. (1989) The cytokine network. Immunol. Today 10, 299-304.
54. [54] Bendtzen, K., Svenson, M., Johnsson, V. and Hippe, E. (1990) Autoantibodies to cytokines-friends or foes? Immunol. Today 11, 167-169.
55. [55] James, K. (1990) Interaction between cytokines and alfa-2-macroglobulin. Immunol. Today 11, 163-166.
56. [56] Morimato, A., Murakami, N., Takada, M., Teshirogi, S. and Watanabe, T. (1987) Fever and acute phase response induced in rabbits by human recombinant interferon-gamma. J. Physiol. 391, 209-218.
57. [57] Dinarello, C.A., Cannon, J.G., Wolff, S.M., Bernheim, H.A., Beutler, B., Cerami, A., Figari, I.S., Palladino, M.A. Jr. and O'Connor, J.V. (1986) Tumor necrosis factor (cachectin) is an endogeneous pyrogen and induces production of interleukin 1. J. Exp. Med. 163, 1433-1450.
58. [58] Perlmutter, D.H., Dinarello, C.A., Punsal, P.I. and Colton, H.R. (1986) Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J. Clin. Invest. 78, 1349-1354.
59. [59] Kampschmidt, R.F., Upchurch, H.F., Eddington, C.L. and Puliam, L.A. (1973) Multiple biological activities of a partially purified leukocytic endogeneous mediator. Am. J. Physiol. 224, 530-538.
60. [60] Oppenheim, J.J., Kovacs, E.J., Matsushima, K. and Durum, S.K. (1986) There is more than one interleukin 1. Immunol. Today 7, 45-56.
61. [61] Gauldie, J., Richards, C., Harnish, D., Lansdorp, P. and Bauman, H. (1987) Interferon b2/13-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA 84, 7251-7255.
62. [62] Bauer, J., Lengyel, G., Bauer, T.M., Acs, G., Gerok, W. (1989) Regu,ation of interleukin-6 receptor expression in human monocytes and hepatocytes. FEBS Lett. 249, 27-30.
63. [63] Heinrich, P.C., Castell., J.V. and Andus, T. (1990) Interleukin-6 and the acute phase response. Biochem. J. 265, 621-636.
64. [64] Maniatis, T., Fritsch, E.F. and Sambrook, J. (1989) Transfer of denatured RNA to nylon membranes. In: Molecular Cloning: A Laboratory Manual, 2nd Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 7.49.
65. [65] Bernatchez, S.F., Merkli, A., Minh, T.L., Tabatabay, C., Anderson, J.M. and Gurny, R. (1994) Biocompatibility of a new semisolid bioerodible poly(orthoester) intended for ocular delivery of 5-fluorouracil. J. Biomed. Mater. Res. 28, 1037-1046.
66. [66] Yun, J.K., DeFife, K., Colton, E., Stack, S., Azeez, A., Cahalan, L., Verhoeven, M., Cahalan, P. and Anderson, J.M. (1995) Human monocyte/macrophage adhesion and cytokine production on poly (tetrafluoroethylene/ hexafluoropropylene) polymers with and without protein preadsorption. J. Biomed. Mater. Res. 29, 257-268.
67. [67] Westermann, J. and Pabst, R. (1990) Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol. Today 11, 406-410.
68. [68] Turner, R.F., Harrison, D.J. and Rajotte, R.V. (1991) Preliminary in vivo biocompatibility studies on perfluorosulphonic acid polymer membranes for biosensor applications. Biomaterials 12, 361-368.
69. [69] Athanasiou, K.A., Niederauer, G.G. and Agrawal, C.M. (1996) Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers, Biomaterials 17, 93-102.
70. [70] Andus, T., Heinrich, P.C., Bauer, J., Tran-Thi, T.A., Decker, K., Maennel, D. and Northoff, H. (1987) Discrimination of hepatocyte-stimulating activity from human recombinant tumor necrosis factor alfa. Eur. J. Immunol. 17, 1193-1197.
71. [71] Anderson, J.M. and Miller, K.M. (1984) Biomaterial biocompatibility and the macrophage. Biomaterials 5, 5-10.
72. [72] Leibovich, S.J. and Ross, R.A. (1976) A macrophage dependent factor that stimulates the proliferation of fibroblasts in vitro. Am. J. Pathol. 84, 501-514.
73. [73] Miller, K.M. and Anderson, J.M. (1988) Human monocyte/macrophage activation and interleukin 1 generation by biomedical polymers. J. Biomed. Mater. Res. 22, 713-731.
74. [74] Schmidt, J.A., Mizel, S.B., Cohen, D. and Green, I. (1982) Interleukin 1, a potential regulator of fibroblast proliferation. J. Immunol. 128, 2177-2182.
75. [75] Thornhill, T.S., Ozuna, R.M., Shortkroff, S., Keller, K., Sledge, C.B. and Spector, M. (1990) Biochemical and histological evaluation of the synovial-like tissue around failed (loose) total joint replacement prosthesis in human subjects and a canine model. Biomaterials 11, 69-72.
76. [76] Krause, T.J., Robertson, F.M., Leisch, J.B., Wasserman, A.J. and Grecos, R.S. (1990) Differential production of IL-1 on the surface of biomaterials. Arch. Surg. 125, 1158-1160.
77. [77] Dinarello, C.A. (1984) Interleukin-1. Rev. Infect. Dis. 6, 51-95.
78. [78] Luger, T.A., Stadler, B.M., Katz, S.I., Oppenheim, J.J. (1980) Epidermal cell (keratinocyte) derived thymocyte activating factor (ETAF). J. Immunol. 127, 1493-1498.
79. [79] Roccatello, D., Bensa, J.C., Coppo, R., Rollino, C. and Diaz, M. (1985) In vitro studying Fc-receptor function in autoimmune diseases. Immunol. Lett. 9, 53-56.
80. [80] Tracey, K.J., Vlassaara, H. and Cerami, A. (1989) Cachectin/tumour necrosis factor. Lancet 1, 1122-1125.
81. [81] Old, L.J. (1985) Tumor necrosis factor (TNF). Science 230, 630-632.
82. [82] Nawroth, P.P. and Stern, D. (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 164, 740-745.
83. [83] Nawroth, P.P., Bank, I., Handley, D., Cassimeris, J., Chess, L. and Stern, D. (1986) Tumor necrosis factor/ cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 163, 1363-1375.
84. [84] Okusawa, S., Yancey, K.B., Van Der Meer, J.W.M., Endres, S. Lonnemann, G., Hefter, K., Frank, M.M., Burke, J.F., Dinarello, C.A. and Gelfand, J.A. (1988) C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alfa. J. Exp. Med. 168, 443-448.
85. [85] Tsujimoto, M., Yokota, S.,Vilcek, J. and Weissmann, G. (1986) Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem. Biophys. Res. Commun. 137, 1094-1100.
86. [86] Nguyen, A.T., Lethias, C., Zingraff, J., Herbelin, A., Naret, C. and Descamps-Latscha, B. (1985) Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int. 34, 67-73.
87. [87] Luger, A., Kovarik, J., Stummvoll, H.K., Urbanska, A. and Luger, T.A. (1987) Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int. 32, 84-88.
88. [88] Kishimoto, T. and Hirano, T. (1988) Molecular regulation of B lymphocyte response. Ann. Rev. Immunol. 6, 485-495.
89. [89] Akira, S., Hirano, T., Taga, T., Kishimoto, T. (1990) Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J. 4, 2860-2867.
90. [90] Hirano, T., Akira, S., Taga, T., Kishimoto, T. (1990) Biological and clinical aspects of interleukin 6. Immunol. Today 11, 443-449.
91. [91] Cenni, E., Ciapetti, G., Cavedagna, D., Di Leo, A. and Pizzoferrato, A. (1993) Production of prostacyclin and fibrinolysis modulators by endothelial cell cultured in the presence of polyethylene terephtalate. J. Biomed. Mater. Res. 27, 1161-1164.
92. [92] Böhler, J., Donauer, K., Köster, W., Schollmeyer, P.J., Wieland, H. and Hörl, W.H. (1991) Biocompatibility of four plasmapheresis membranes in patients treated for hypercholesterolemia. Am. J. Nephrol. 11, 479-485.
93. [93] Paul, D., Malsch, G., Bossin, E., Wiese, F., Thomaneck, U., Brown, G.S., Werner, H. and Falkenhagen, D. (1990) Chemical modification of cellulosic membranes and their blood compatibility. Artif. Organs 14, 122-125.
94. [94] Craddock, P.R., Fehr, J., Dalmasso, A.P., Brigham, K.L. and Jacob, H.S. (1977) Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activaion by dialyzer cellophane membranes. J. Clin. Invest. 59, 879-888.
95. [95] Sawada, K., Malchesky, P.S., Guidubaldi, J.M., Sueoka, A. and Shimoyama, T. (1993) In vitro evaluation of a relationship between hu-an se2um-or plasma-material interaction and polymer bulk hydroxyl and surface oxygen content. ASAIO J. 39, 910-917.
96. [96] Sawada, K., Shimoyama, T., Malchesky, P.S., Goldcamp, J.B. and Omokawa, S. (1993). Evaluation of a relationship between polymer bulk hydroxyl and surface oxygen content and in vitro serum-material interaction. J. Biomed. Mater. Res. 27, 547-555.
97. [97] Tigchelaar, T., Monnink, S.H., Haan, J., Tabuchi, N. and van Oeveren, W. (1995) Platelet function analysis after in vitro treatment with hemostasis-affecting components. Semin. Thromb. Hemost. 21. 71-76.
98. [98] Benzina, A., Kruft, M.A., Bar, F., van der Veen, F.H., Bastiaansen, C.W., Heijnen, V., Reutelingsperger, C. and Koole, L.H. (1994) Studies on a new rediopaque polymeric biomaterial. Biomaterials 15, 1122-1128.
99. [99] Desai, N.P. and Hubbell, J.A. (1989) The short-term blood biocompatibility of poly(hydroxyethyl methacrylate-co-methyl methacrylate) in an in vitro flow system measured by digital videomicroscopy. J. Biomater. Sci. Polym. Ed. 1, 123-146.
100. [100] Nagaoka, S. and Akashi, R. (1990) Low friction hydrophilic surface for medical devices. J. Bioact. Compat. Polymers 5, 212-226.
101. [101] Lee, K.Y., Ha, W.S. and Park, W.H. (1995) Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials 16, 1211-1216.
102. [102] Matsuda, T. and Inoue, K. (1990) Novel photoreactive surface modification technology for fabricated devices. Tran. ASAIO 36, M161-164.
103. [103] Clarotti, G., Schue, F., Sledz, J., Ait-Ben-Aoumar, A., Geckeler, K.E., Orsetti, A. and Palcirac, G. (1992) Modification of the biocompatible and haemocompatible properties of polymer substrates by plasma-deposited fluorocarbon coatings. Biomaterials 13, 832-840.
104. [104] Sheppard, J.I., McClung, W.G. and Feuerstein, I.A. (1994) Adherent platelet morphology on absorbed fibrinogen: effects of protein incubation time and albumin addition. J. Biomed. Mater. Res. 28, 1175-1186.
105. [105] Stanislawski, L., De Nechaud, B. and Christel, P. (1995) Plasma protein adsorption to artificial ligament fibers. J. Biomed. Mater. Res. 29, 315-323.
106. [106] Weaver, R.E. and Goebel, W.M. (1990) Reactions to acrylic resin dental prostheses. J. Prosthet. Dent. 43, 138-142.
107. [107] Monteny, E., Oleffe, J. and Donkerwolke, M. (1978) Methylmethacrylate hypers%nsitivity in a patients with cemented endoprosthesis. Acta Orthop. Scand. 49, 554-556.
108. [108] R5mpf, .W., Seubert, S., Seubert, A., Jaegger, M., Lowitz, H.D., Valentin, B., Schunemann, B., Thon, P., Thonnies, H.J., Quellhorst, E. and Soheler, F. (1987) Ethylene-oxide induced IgE antibodies and symptomatology in dialysis patients. Contrib. Nephrol. 59, 145-153.
109. [109] Bommer, J., Frosch, P., Schindele, A., Barth, H.P., Ritz, E. and Reitinger, J. (1987) Ethylene oxide sterilization. A risk for hemodialysis patients. Contrib. Nephrol. 59, 154-161.
110. [110] Jayakrishnan, A. and Jameela, S.R. (1996) Glutaraldehyde as a fixative in bioprostheses and drug delivery matrices. Biomaterials 17, 471-484.
111. [111] Bajpai, P.K. (1985) Immunological aspects of treated natural tissue prostheses. In: Williams, D.F. (Ed.), Biocompatibility of Tissue Analogues. CRC Press, Boca Raton, FL, pp. 5-25.
112. [112] Slanczka, D.J., Russo, D.A., Bajpai, P.K. and Woodroof, E.A. (1979) Immunogenicity of tanned tissue used in heart valve replacement. Proc. 7th N. Engl. Bioeng. Conf. 197-200.
113. [113] Bajpai, P.K., Russo, D.A., Slanczka, D.J. and Weiskettel, K.E. (1982) Immunogenicity of glutaraldehyde treated tissue used in heart valve replacement. In: Winter, G.D., Gibbson, D.F. and Plenk, H. (Eds.), Advances in Biomaterials. Wiley, Chichester, pp. 603-612.
114. [114] Kossovsky, N., Heggers, J.P. and Robson, M.C. (1987) Experimental demonstration of the immunogenicity of silicone-protein complexes. J. Biomed. Mater. Res. 21, 1125-1133.
115. [115] Varga, J., Schumacher, R. and Jimenez, S.A. (1989) Systemic sclerosis after augmentation mammoplasty with silicone implants. Ann. Intern. Med. 111, 377-383.
116. [116] Baldwin, C.M. and Kaplan, E.N. (1983) Silicone-induced human adjuvant disease? Ann. Plast. Surg. 10, 270-273.
117. [117] Foster, W.C., Springfield, D.S. and Brown, K.L.B. (1983) Pseudotumor of the arm associated with rupture of silicone-gel breast prostheses. J. Bone Joint Surg. (Am.) 65, 548-551.
118. [118] Smith, R.J., Atkinson, R.E. and Jupiter, J.B. (1985) Silicone synovitis of the wrist. J. Hand Surg. 10A, 47-61.
119. [119] Ashley, F.L. (1970) A new type of breast prostheses: preliminary report. Plast. Reconstr. Surg. 45, 421-424.
120. [120] Ashley, F.L. (1972) Further studies on the natural-Y breast prostheses. Plast. Reconstr. Surg. 49, 414-418.
121. [121] Brown, J.M. (1995) Polyurethane and silicone: myths and misconceptions. J. Intraven. Nurs. 18, 120-122.
122. [122] Spector, M., Cease, C. and Xong-Li, X. (1989) The local tissue response to biomaterials. In: D.F. Williams (Ed.), Critical Reviews in Biocompatibility. CRC Press, Boca Raton, FL, pp. 260-295.
123. [123] Sinigaglia, F., Scheidegger, D., Garotta, G., Schepter, R., Pletscher, M. and Lanzavecchia, A. (1985) Isolation and characterization of Ni-specific T cell clones from patients with Ni contact dermatitis. J. Immunol. 135, 3929-3932.
124. [124] Gimenez-Camarasa, J.M., Garcia-Calderon, P., Asensio, J. and De Moragas, J.M. (1975) Lymphocyte transformation test in allergic contact nickel dermatitis. Br. J. Dermatol. 92, 9-15.
125. [125] Bravo, I., Carvalho, G.S., Barbosa, M.A. and deSousa, M. (1990) Differential effects of eight ions on lymphocyte differentiation antigens in vitro. J. Biomed. Mater. Res. 24, 1059-1068.
126. [126] McGee, J.P., Davis, S.S. and O'Hagan, D.T. (1994) The immunogenicity of a model protein entrapped in poly-(lactide-co-glycolide) microparticles prepared by a novel phase separation technique. J. Control. Release 31, 55-60.
127. [127] Duncan, R., Kopeček, J. (1984) Soluble synthetic polymers as potential drug carriers. Adv. Polym. Sci. 57, 51-101.
128. [128] Kopeček, J. (1984) Synthesis of tailor-made soluble polymeric drug carriers. In: J.M. Anderson and S.W. Kim (Eds.), Recent Advances in Drug Delivery Systems. Plenum Press, New York, pp. 41-62.
129. [129] Duncan, R., Kopečkova-Rejmanová, P., Strohalm, J., Hume, I.C., Cable, H.C., Pohl, J., Lloyd, J.B. and Kopeček, J. (1987) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer 55, 165-174.
130. [130] Duncan, R., Kopečková, P., Strohalm, J., Hume, I.C., Lloyd, J.B. and Kopeček, J. (1988) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukemia. Br. J. Cancer 57, 147-156.
131. [131] Řihová, B., Kopečková, P., Strohalm, J., Rossmann, P., Větvička, V. and Kopeček, J. (1988) Antibody-directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46, 199-114.
132. [132] Kopeček, J., Rejmanová, P., Strohalm, J., Ulbrich, K., Řihová, B. Chytrý, V, Duncan, R. and Lloyd, J.B. (1991) Synthetic polymeric drugs. US Patent 5 037 883
133. [133] Řihová, B., Jegorov, A., Strohalm, J., Maťha, V., Rossmann, P., Fornůsek, L. and Ulbrich, K. (1992) Antibody-targeted cyclosporin A. J. Control. Release 19, 25-40.
134. 6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy-1.2 antibodies. J. Control. Release 25, 71-87.
135. [135] Řihová, B., Ulbrich, K., Kopeček, J. and Mančal, P. (1983) Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers-potential hapten or drug carriers. Folia Microbiol. 28, 217-227.
136. [136] Řihová, B., Kopeček, J., Ulbrich, K., Pospišil, M. and Mančal, P. (1984) Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials 5, 143-148.
137. [137] Řihová, B., Kopeček, J., Ulbrich, K. and Chytrý, V. (1985) Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers. Makromol. Chem. 9, 13-24.
138. [138] Řihová, B., Bilej, M., Větvička, V., Ulbrich, K., Strohalm, J., Kopeček, J. and Duncan, R. (1989) Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10, 335-342.
139. [139] Bujia, J., Reitzel, K. and Sittinger, M. (1995) In vitro cultivation of cartilage tissue for reconstructive surgery: effect of L( + )-lactate and glycolate on cultivated human chondrocytes. Laryngorhinootologie 74, 183-187.
140. [140] Tucci, M.A. and Benghuzzi, H.A. (1995) Quantitative analysis of the effect of surface impregnation with biomedical polymers on the proliferation rate of HeLa cells in culture. Biomed. Sci. Instrum. 31, 135-140.
141. [141] van Sliedregt, A., Radder, A.M., deGroot, K. and van Blitterswijk, C.A. (1992) In vitro biocompatibility testing of polylactides. Part I. Proliferation of different cell types. J. Mater. Sci. Mater. Med. 3, 365-370.
142. [142] Choksakulnimitr, S., Masuda, S., Tokuda, H., Takakura, Y., Hashida, M. (1995) In vitro cytotoxicity of macromolecules in different cell culture systems. J. Control. Release 34, 233-241.
143. [143] Larsen, N.E., Pollak, C.T., Reiner, K., Leshchiner, E. and Balazs, E.A. (1993) Hylan gel biomaterial: dermal and immunologic compatibility. J. Biomed. Mater. Res. 27, 1129-1134.
144. [144] Laurencin, C., Domb, A., Morris, C., Brown, V., Chasin, M., McConnell, R., Lange, N. and Langer, R. (1990) Poly(anhydride) administration in high doses in vivo: studies of biocompatibility and toxicology. J. Biomed. Mater. Res. 24, 1463-1481.
145. [145] Ryser, H.J.P. and Shen, W.C. (1978) Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc. Natl. Acad. Sci. USA 75, 3867-3872.
146. [146] Gill, T.J. III., Kunz, H.W., Could, H.J. and Doty, P. (1964) Studies on synthetic polypeptide antigens. XI. The antigenicity of optically isomeric synthetic polypeptides. J. Biol. Chem. 239, 1107-1114.
147. [147] Vermeersch, H. and Remon, J.P. (1994) Immunogenicity of poly-D-lysine, a potential polymeric drug carrier. J. Control. Release 32, 225-229.
148. [148] Bogdanov, A.A. Jr., Weissleder, R., Frank, H.W., Bogdanova, A.V., Nossif, N., Schaffer, B.K., Tsai, E., Papisov, M.I. and Brady, T.J. (1993) A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. Radiology 187, 701-706.
149. [149] Inada, Y., Matsushima, A., Kodera, Y. and Nishimura, H. (1990) Polyethylene glycol (PEG)-protein conjugates: application to biomedical and biotechnological processes. J. Bioact. Compat. Polym. 5, 343-364.
150. [150] Burnham, B. (1994) Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 51, 210-218.
151. [151] Tsutsumi, Y., Kihira, T., Tsunoda, S.-I., Okada, N., Kaneda, Y., Ohsugi, Y., Miyake, M., Nakagawa, S. and Mayumi, T. (1995) Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity. J. Control. Release 33, 447-451.
152. [152] Abuchowski, A., McCoy, J.R., Palczuk, N.C., Van Es, T. and Davis, F.F. (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582-3586.
153. [153] Abuchowski, A., Van Es, T., Palczuk, N.C. and Davis, F.F. (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252, 3578-3581.
154. [154] Sehon, A.H. (1982) Suppression of IgE antibody response with tolerogenic conjugates of allergens and haptens. Prog. Allergy 32, 161-202.
155. [155] Fuertges, F. and Abuchowski, A. (1990) The clinical efficacy of polyethylene glycol-modified proteins. J. Control. Release 11, 139-148.
156. [156] Katre, N.V. (1990) Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 144, 209-213.
157. [157] Sehon, A.H. (1991) Suppression of antibody responses by chemically modified antigens. Int. Arch. Allergy Appl. Immunol. 94, 11-20.
158. [158] Hershfield, M.S., Chaffee, S., Koro-Johnson, L., Mary, A., Smith, A.A. and Short, S.A. (1991) Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl. Acad. Sci. USA 88, 7185-7189.
159. [159] Somack, R., Saifer, M.G. and Williams, L.D. (1991) Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41 000-72 000 daltons). Free Radic. Res. Commun. 12/13, 553-562.
160. [160] Nucci, M.L., Shorr, R. and Abuchowski, A. (1991) The therapeutic value of poly(ethylene glycol)-modified proteins. Adv. Drug. Deliv. Rev. 6, 133-151.
161. [161] Sehon, A.H. (1992) Suppression of antibody responses by conjugates of antigens and monomethoxypoly (ethylene glycol). In: J.M. Harris (Ed.), Poly(ethylene glycol) Chemistry. Plenum Press, New York, pp. 139-153.
162. [162] Maeda, H., Kimura, M., Sasaki, I., Hirose, Y. and Konno, T. (1992) Toxicity of bilirubin and detoxification of PEG-bilirubin oxidase conjugate: a new tactic for treatment of jaundice. In: J.N. Harris (Ed.), Poly-(ethylene glycol) Chemistry. Plenum Press, New York, pp. 153-169.
163. [163] MacEwen, E.G., Rosental, R.C., Fox, L.E., Loar, A.S.D. and Kurzman, I.D. (1992) Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma. J. Vet. Intern. Med. 6, 230-234.
164. [164] Malik, F., Delgado, C., Knusli, C., Irvine, A.E., Fisher, D. and Francis, G.E. (1992) Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity. Exp. Hematol. 20, 1028-1035.
165. [165] Wang, Q-CH., Pai, L.H., Debinski, W., FitzGerald, D.J. and Pastan, I. (1993) Polyethylene glycol-modified chiomeric toxin composed of transforming growth factor alfa and Pseudomonas exotoxin. Cancer Res. 53, 4588-4594.
166. [166] Katre, N.V., Knauf, M.J. and Laird, W.J. (1987) Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci. USA 84, 1487-1491.
167. [167] Kita, Y., Rohde, M.F., Arakawa, T. and Fagin, K.D. (1990) Characterization of a polyethylene glycol conjugate of recombinant human interferon-gamma. Drug Des. Deliv. 6, 157-167.
168. [168] Tsutsumi, Y., Kihira, T., Yamamoto, S., Kuho, K., Nakagawa, S., Miyake, M., Horisawa, Y., Kanamori, T., Ikegami, H. and Mayumi, I. (1994) Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its antitumor potency. Jpn. J. Cancer Res. 85, 9-12.
169. [169] Niven, R.W., Whitcomb, K.L., Shaner, L., Ralph, L.D., Habberfield, A.D. and Wilson, J.V. (1994) Pulmonary absorption of polyethylene glycolated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF). J. Control. Release 32, 177-189.
170. [170] Abuchowski, A., McCoy, J.R., Palczuk, N.C., Van Es, T. and Davis, F.F. (1976) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582-3586.
171. [171] Abuchowski, A., Van Es, T., Palczuk, N.C., McCoy, J.R. and Davis, F.F. (1979) Treatment of L51784 tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase. Cancer Treat. Rep. 63, 1127-1132.
172. [172] Řihová, B. and Kopeček. J. (1985) Biological properties of targetable poly[N-(2-hydroxypropyl)methacrylamide]-antibody conjugates. J. Control. Release 2, 289-310.
173. [173] Flanagan, P.A., Duncan, R., Řihová, B., Šubr, V. and Kopeček, J. (1990) Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates in A/J and B10 mice. J. Bioact. Compat. Polym. 5, 151-166.
174. [174] Sawada, K., Shimoyama, T., Malchesky, P.S., Goldcamp, J.B. and Omokawa, S. (1993) Evaluation of a relationship between polymer bulk hydroxyl and surface oxygen content and in vitro serum-material interaction. J. Biomed. Mater. Res. 27, 547-555.
175. [175] Baker, P.J., Lint, T.F., McLeod, B.C., Behrends, C.L. and Gewurz, J. (1975) Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis by polyanions and polycations. J. Immunol. 114, 554-558.
176. [176] Loos, M., Volanakis, J.E. and Stroud, R.M. (1976) Mode of interaction of different polyanions with the first (C1,C1), the second (C2) and the fourth (C4) component of complement-III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry 13, 789-791.
177. [177] Raepple, E., Hill, H.U. and Loos, M. (1976) Mode of interaction of different polyanions with the first (C1,C1), the second (C2) and the fourth (C4) component of complement-I. Effect of fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry 13. 251-255.
178. [178] Webster, G.W. and McArthur, W.P. (1981) Inhibition of the classical and alternative pathway of human and guinea pig complement by pyran copolymer. Int. Arch. Allergy 66, 304-309.
179. [179] Šimečková, J., Řihová, B., Plocová, D. and Kopeček, J. (1986). The activity of complement in the presence of N-(2-hydroxypropyl)methacrylamide copolymers. J. Bioact. Compat. Polym. 1, 20-31.
180. [180] Townsend, A.R.M., Gotch, F.M. and Davey, J. (1985) Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42, 457-467.
181. [181] Řihová, B. (1995) Presentation of antigen and MHC-restricted unresponsiveness. Folia Biol. 41, 140-162.
182. [182] Volfová, I., Řihová, B., Větvička, V., Rossmann, P. and Ulbrich, K. (1992) Biocompatibility of biopolymers. J. Bioact. Compat. Polym. 7, 175-190.
183. [183] Seymour, L.W., Duncan, R., Strohalm. J. and Kopeček, J. (1987) Effect of molecular weight of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal and intravenous administration in rats. J. Biomed. Mater. 21, 1341-1358.
184. [184] Duncan, R. and Lloyd, J.B. (1984) Biological evaluation of soluble synthetic polymers as drug carriers. In: J.M. Anderson and S.W. Kim (Eds.), Recent Advances in Drug Delivery Systems. Plenum Press, New York, pp. 9-22.
185. 125I]daunomycin. J. Control. Release 10, 37-49.
186. [186] Vitetta, E.S., Thorpe, P.E. and Uhr, J.W. (1993) Immunotoxins: magic bullets or misquided missiles? Immunol. Today 14, 252-264.
187. [187] Takakura, Y., Fujita, T., Furitsu, H., Nishikawa, M., Sezaki, H. and Hashida, M. (1994) Pharmacokinetics of succinylated proteins and dextran sulfate in mice: implications for hepatic targeting of protein drugs by direct succinylation via scavenger receptors. Int. J. Pharm. 105, 19-29.
188. [188] Tucci, M.A. and Benghuzzi, H.A. (1994) The role of different biomaterials on adhesion of nontransformed buccal epithelial cells. Biomed. Sci. Instrum. 30, 205-212.